DCHPF News and Press, Dechra Pharmaceuticals Plc From 05/23/22

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Growth Fund (the "Fund") declined 13.33% (Institutional Shares) during the quarter ended March 31, 2022. We foc...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...

Dechra Pharmaceuticals PLC (DPHAY) Q2 2022 Earnings Conference Call February 21, 2022 4:00 AM ET Company Participants Ian Page - CEO Paul Sandland - CFO Conference Call Participants Max Herrmann - Stifel Anand Date - HSBC Mike Mitchell - Panmure Gordon Andrew Whitney - Investec Zoe Karamanoli...

The following slide deck was published by Dechra Pharmaceuticals PLC in conjunction with their 2022 Q2 earnings call. For further details see: Dechra Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation

Morrisons (OTCPK:MRWSF +2.5%), the fourth largest UK supermarket chain, is poised to enter the FTSE 100 index. The company's shares surged 60% since June to a valuation of $9.6B after it received offers from private equity firms. Its inclusion in the index could be short given the bidders com...

The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets. Impressive margins and high growth is apparent across consumabl...

U.K.-listed animal medicine maker Dechra ([[DPHAY]], [[DCHPF]]) published its annual report . The results were decent, but the strong share price run-up emphasises that the shares are not valued on fundamentals. I continue to think that the company is highly overvalued and is a definite sell....

Dechra ([[DPHAY]], [[DCHPF]]) is a U.K.-based animal medicines group. Manufacturing across seven sites including the U.K., Belgium and the U.S., they have a wide international sales reach with sales and marketing teams in 25 countries and 68 countries in which their products are sold via distr...